The Lymphocyte Response Assay (LRA) by ELISA/ACT®, developed by ELISA/ACT Biotechnologies LLC (EAB), makes it possible to examine the general health of a patient’s immune system by monitoring delayed hypersensitivity responses to over 500 common substances. The tests identify reactive substances, which may be provoking the patient’s chronic condition. Patients are also provided a personalized treatment plan to help eliminate these sensitivities and restore overall health.
LRA by ELISA/ACT® tests are the first and only blood tests that provide a complete evaluation of the body’s delayed immune response. A special blood drawing system, combined with simple patient test preparation instructions, prevents activation of lymphocytes prior to analysis. ELISA/ACT receives the patient’s one-ounce blood sample within 24 hours and analyzes it promptly.